Andreas Fritsche

Andreas Fritsche

Auto-generated profile, based on publicly available information

Andreas Fritsche

Helmholtz Zentrum München und Deutsches Zentrum für Diabetesforschung (DZD e. V.), Neuherberg, Deutschland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2007 in Diabetologia
Verified
Journal Article
Open access
PDF file
SSS. A. Schäfer
S. A. Schäfer
OTO. Tschritter
O. Tschritter
FMF. Machicao
F. Machicao
CTC. Thamer
C. Thamer
NSNorbert Stefan
Norbert Stefan
AFA. Fritsche
A. Fritsche
Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The transcription factor TCF7L2 is an essential factor for glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells. We studied whether a defect in the enteroinsular axis contributes to impaired insulin secretion in carriers of TCF7L2 polymorphisms.

9 February 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
KKK. Kirchhoff
K. Kirchhoff
FMF. Machicao
F. Machicao
AHA. Haupt
A. Haupt
SSS. A. Schäfer
S. A. Schäfer
OTO. Tschritter
O. Tschritter
AFA. Fritsche
A. Fritsche

5 April 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ASAnja Schork
Anja Schork
JSJanine Saynisch
Janine Saynisch
AVAndreas Vosseler
Andreas Vosseler
BJBenjamin Assad Jaghutriz
Benjamin Assad Jaghutriz
NHNils Heyne
Nils Heyne
FAFerruh Artunc
Ferruh Artunc
SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2 diabetes and have been shown to reduce body weight. However, it is unclear which body compartments are reduced and to what extent. In this longitudinal observational study, we analyzed the body composition of 27 outpatients with type 2 diabetes mellitus during the first week and up to 6 months after initiation of treatment with SGLT2-inhibitors (n = 18 empagliflozin, n = 9 dapagliflozin) using bioimpedance spectroscopy (BCM, Fresenius). Fluid status of hypertensive patients taking medication with hydrochlorothiazide (n = 14) and healthy persons (n = 16) were analyzed for comparison. At 6 months, HbA1c decreased by 0.8% (IQR 2.3; 0.4), body weight and BMI by 2.6 kg (1.5; 9.3) and 0.9 kg/m2 (0.4; 3.3), respectively. Bioimpedance spectroscopy revealed significant decrease in adipose tissue mass and fat tissue index while lean tissue parameters remained stable. Overhydration (OH) and extracellular water (ECW) decreased by − 0.5 L/1.73 m2 (− 0.1; − 0.9) and − 0.4 L/1.73 m2 (− 0.1; − 0.8) at day 3, respectively, and returned to the initial value after 3 and 6 months. Plasma renin activity increased by 2.1-fold (0.5; 3.6) at 1 month and returned to the initial level at month 3 and 6. Fluid status of patients with SGLT2 inhibitors after 6 months showed no difference from that of hypertensive patients taking hydrochlorothiazide or healthy persons. Body weight reduction under the treatment with SGLT2-inhibitors is caused by reduction of adipose tissue mass and transient loss of extracellular fluid, which is accompanied by upregulation of renin–angiotensin–aldosterone system (RAAS). Permanent loss of extracellular water does not occur under SGLT2 inhibition.

27 December 2013 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
MHMartin Heni
Martin Heni
PSPatricia Schöpfer
Patricia Schöpfer
APAndreas Peter
Andreas Peter
TSTina Sartorius
Tina Sartorius
AFAndreas Fritsche
Andreas Fritsche
AHAnita M. Hennige
Anita M. Hennige

14 March 2011 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
GSGuenther Silbernagel
Guenther Silbernagel
JMJuergen Machann
Juergen Machann
SUSusanne Unmuth
Susanne Unmuth
FSFritz Schick
Fritz Schick
NSNorbert Stefan
Norbert Stefan
AFAndreas Fritsche
Andreas Fritsche
An increasing amount of fructose in the diet is suggested to play a causal role in the pathogenesis of the metabolic syndrome, type 2 diabetes and fatty liver. Our aim was to investigate and compare the effects of very high fructose and very high glucose in hyperenergetic diets on glucose and lipid metabolism and on fat depots in healthy humans. We conducted an exploratory, prospective, randomised, single-blinded, intervention trial. Participants in addition to a balanced weight-maintaining diet received 150 g of fructose or glucose/d for 4 weeks. Insulin sensitivity was estimated from oral glucose tolerance tests. Visceral and subcutaneous abdominal fat was determined with MRI. Liver fat and intramyocellular lipids of the tibialis anterior muscle were measured with1H magnetic resonance spectroscopy. A total of twenty healthy subjects (fructose groupn10 and glucose groupn10; twelve males and eight females) completed the study. They had a mean age of 30·5 (sem2·0) years and a mean BMI of 25·9 (sem0·5) kg/m2. Insulin sensitivity appeared to decrease both in the fructose and glucose groups. TAG markedly increased in the fructose group. No strong alterations or treatment effects were found for liver fat, visceral fat, subcutaneous abdominal fat and intramyocellular lipids of the tibialis anterior muscle. In conclusion, the effects of very high fructose and very high glucose in hyperenergetic diets on glucose metabolism and body fat composition were not different in the healthy participants of the present study. However, elevation of plasma TAG seemed to be fructose-specific.

10 May 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
AWAndrew R. Wood
Andrew R. Wood
AJAnna Jonsson
Anna Jonsson
AJAnne U. Jackson
Anne U. Jackson
NWNan Wang
Nan Wang
NLNienke van Leewen
Nienke van Leewen
TFTimothy M. Frayling
Timothy M. Frayling
Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed the largest genome-wide association study of first-phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 individuals without diabetes from 10 studies. We aimed to refine the mechanisms of 178 known associations between common variants and glycemic traits and identify new loci. Thirty type 2 diabetes or fasting glucose–raising alleles were associated with a measure of first-phase insulin secretion at P < 0.05 and provided new evidence, or the strongest evidence yet, that insulin secretion, intrinsic to the islet cells, is a key mechanism underlying the associations at the HNF1A, IGF2BP2, KCNQ1, HNF1B, VPS13C/C2CD4A, FAF1, PTPRD, AP3S2, KCNK16, MAEA, LPP, WFS1, and TMPRSS6 loci. The fasting glucose–raising allele near PDX1, a known key insulin transcription factor, was strongly associated with lower first-phase insulin secretion but has no evidence for an effect on type 2 diabetes risk. The diabetes risk allele at TCF7L2 was associated with a stronger effect on peak insulin response than on C-peptide–based insulin secretion rate, suggesting a possible additional role in hepatic insulin clearance or insulin processing. In summary, our study provides further insight into the mechanisms by which common genetic variation influences type 2 diabetes risk and glycemic traits.